Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists
Markus Glatzer, Pawel Leskow, Francesca Caparrotti, Olgun Eliçin, Markus Furrer, Franco Gambazzi, André Dutly, Hans Gelpke, Matthias Gückenberger, Jürg Heuberger, Rolf Inderbitzi, Stefano Cafarotti, Wolfram Karenovicŝ, Peter Kestenholz, Gregor J. Kocher, Peter Kraxner, Thorsten Krueger, Francesco Martucci, Christoph Oehler, Mahmut Özsahin, Alexandros Papachristofilou, Dirk Wagnetz, Kathrin Zaugg, Daniel R. Zwahlen, Isabelle Opitz, Paul Martin Putora
Abstract
BACKGROUND: Stage III N2 non-small cell lung cancer (NSCLC) is a very heterogeneous disease associated with a poor prognosis. A number of therapeutic options are available for patients with Stage III N2 NSCLC, including surgery [with neoadjuvant or adjuvant chemotherapy (CTx)/neoadjuvant chemoradiotherapy (CRT)] or CRT potentially followed by adjuvant immunotherapy. We have no clear evidence demonstrating a significant survival benefit for either of these approaches, the selection between treatments is not always straightforward and can come down to physician and patient preference. The very heterogeneous definition of resectability of N2 disease makes the decision-making process even more complex. METHODS: We evaluated the treatment strategies for preoperatively diagnosed stage III cN2 NSCLC among Swiss thoracic surgeons and radiation oncologists. Treatment strategies were converted into decision trees and analysed for consensus and discrepancies. We analysed factors relevant to decision-making within these recommendations. RESULTS: For resectable "non-bulky" mediastinal lymph node involvement, there was a trend towards surgery. Numerous participants recommend a surgical approach outside existing guidelines as long as the disease was resectable, even in multilevel N2. With increasing extent of mediastinal nodal disease, multimodal treatment based on radiotherapy was more common. CONCLUSIONS: Both, surgery- or radiotherapy-based treatment regimens are feasible options in the management of Stage III N2 NSCLC. The different opinions reflected in the results of this manuscript reinforce the importance of a multidisciplinary setting and the importance of shared decision-making with the patient.